InvestorsHub Logo
Followers 33
Posts 2840
Boards Moderated 2
Alias Born 10/24/2015

Re: None

Sunday, 04/03/2022 7:11:48 PM

Sunday, April 03, 2022 7:11:48 PM

Post# of 151
NKX101 (R/R AML and higher-risk MDS): Dose escalation should be finished in Q3, dose expansion in H1 2023, and potential pivotal trial(s) in 2H 2023.

NKX101 (certain solid tumours): They will amend the IND in Q4 and plan to start a PhI sometime in 2023.

NKX019 (CD19+ B-cell malignancies): Dose escalation should be finished in Q3, dose expansion in H1 2023, and potential pivotal trial(s) in 2H 2023.

As for the programs with CRSP, no info to when they could be moving into the clinic as of yet.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NKTX News